Drug Trial Radar · NCT04915404
Berubicin in Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV)
Last checked: Nov 19, 2026Latest source record: Jun 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
5
Actual
Start
Dec 7, 2022
Primary completion
Dec 30, 2023
Study completion Dec 30, 2023
Sponsor
- Lead sponsor
- WPD Pharmaceuticals Sp. z o.o.Industry
- Sponsor type
- Industry
- Collaborators
- Worldwide Clinical Trials; National Center for Research and Development, Poland
- First posted
- Jun 7, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label, Phase 1b/2 efficacy and safety study of Berubicin utilizing a Simon's 2-stage design to confirm the efficacy (or futility) of a single arm of Berubicin treatment, administered at the recommended Phase 2 dose (RP2D) identified in Phase 1 studies (7.5 mg/m2 Berubicin HCl), on the endpoint of ORR in up to approximately 61 patients. A central reader will determine the radiologic responses for each patient according to m RANO criteria. The responder criteria for this Simon's design will be based on objective response criteria defined as individual patients achieving CR or PR per m-RANO criteria within 6 months from baseline.
Conditions
- Recurrent Glioblastoma Multiforme
Interventions
Berubicin HydrochlorideDrug
Berubicin intravenously infused will be administered at a dose of 7.1 mg/m2 as free base (equivalent to 7.5 mg/m2 Berubicin HCl) as a 2-hour intravenous (IV) infusion once daily for 3 consecutive days followed by 18 days off study drug (each cycle = 21 days).
Primary outcomes
What the sponsor says the trial is designed to measure.
- objective response rate (ORR)Time frame: 6 months
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Uniwersyteckie Centrum Kliniczne Klinika Onkoligii i Radioterapii
Gdansk, Poland
Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie,Państwowy Instytut Badawczy w Warszawie,Klinika Nowotworów Głowy i Szyi
Warsaw, Poland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.